Receptor agonists

DGAP-News: Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Pharmacodynamics, Receptor agonists, Health sciences, Biology, Psoriasis, Agonist, Inverse agonist, IMU-935, Immunic, Inc., IMU-935, IMMUNIC, INC.

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORt Inverse Agonist

Key Points: 
  • Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORt Inverse Agonist
    The issuer is solely responsible for the content of this announcement.
  • The multiple ascending dose part of the phase 1 trial with 14-day daily dosing in healthy volunteers is ongoing and progressing.
  • Immunic's management team will host a virtual R&D Day today, July 12, 2021, at 4:00 p.m. Eastern Time to discuss the updates on the preclinical and clinical development of the company's IMU-935 program.
  • IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome.

2021 Global Methylamine Hydrobromide (CAS 6876-37-5) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Chemicals, Plastics, Manufacturing, Psychoactive drugs, Drugs, Receptor agonists, Entheogens, Euphoriants, MDMA, Methamphetamines, Stimulants, Hydrobromide, Methylamine

The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Methylamine hydrobromide.
  • The Methylamine hydrobromide global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Methylamine hydrobromide market trends and forecast, distinguish Methylamine hydrobromide manufacturers and suppliers.

Largest Real-World Study of Bioabsorbable Testosterone Pellets in Men and Women Shows Low Complication Rates Over 7 Years and 1.2 Million Implants

Retrieved on: 
Tuesday, June 1, 2021
Technology, Health, General Health, Women, Seniors, MEN, Other Science, Other Technology, Research, Consumer, Science, Organic compounds, Receptor agonists, Medical specialties, Estrogens, Testosterone, Androstanes, Enones, GABAA receptor positive allosteric modulators, Androgen replacement therapy, Masculinizing hormone therapy

Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.

Key Points: 
  • Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.
  • The use of testosterone therapy in men has been increasing progressively year over year since the 1990s.
  • The study is the largest reported retrospective study to evaluate the continuation and complication rates of testosterone pellet implants.
  • We are dedicated to helping patients live better, longer by changing the way healthcare is practiced on a global level.

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 19, 2021
Psychoactive drugs, Drugs, Receptor agonists, Amifampridine, Aminopyridines, XC2, Catalyst, MDMA, Catalyst Pharmaceuticals

With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases.

Key Points: 
  • With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases.
  • Catalyst\'s New Drug Application for Firdapse\xc2\xae (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the\xc2\xa0U.S.
  • Copies of Catalyst\'s filings with the SEC are available from the SEC, may be found on Catalyst\'s website, or may be obtained upon request from Catalyst.
  • Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.\n'

Antares Pharma Reports First Quarter 2021 Financial and Operating Results

Retrieved on: 
Thursday, May 6, 2021
Steroids, Receptor agonists, Androstanes, Organic compounds, Triptans, Ketones, Testosterone, Testosterone enanthate, Sumatriptan, Subcutaneous, Forward-looking statement, XC2

Furthermore, our commercial organization implemented an enhanced targeting strategy that reinforces the expansion opportunities for XYOSTED and the relaunch of NOCDURNA.

Key Points: 
  • Furthermore, our commercial organization implemented an enhanced targeting strategy that reinforces the expansion opportunities for XYOSTED and the relaunch of NOCDURNA.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.
  • The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.

Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

Retrieved on: 
Monday, May 3, 2021
Steroids, Receptor agonists, Androstanes, Organic compounds, Triptans, Ketones, Testosterone enanthate, Testosterone, Sumatriptan, Subcutaneous, Autoinjector, Teva Pharmaceuticals

Vogiatzi commented, \xe2\x80\x9cWe were pleased to be able to share this novel data extrapolation with our colleagues and peers.

Key Points: 
  • Vogiatzi commented, \xe2\x80\x9cWe were pleased to be able to share this novel data extrapolation with our colleagues and peers.
  • There are currently no approved autoinjectors to deliver subcutaneous testosterone in this medically underserved population.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

New startup Trūman Rx launches to expand access to testosterone therapy

Retrieved on: 
Wednesday, April 14, 2021
Organic compounds, Chemical compounds, Receptor agonists, Testosterone, Androstanes, Enones, Estrogens, GABAA receptor positive allosteric modulators, Telehealth, Androgen replacement therapy, Harry S. Truman

b'DENVER, April 14, 2021 /PRNewswire/ -- In an effort to increase access to testosterone replacement therapy for men, Colorado-based startup Truman Rx (Truman) is launching an online, innovative telehealth service for testosterone replacement therapy (TRT).

Key Points: 
  • b'DENVER, April 14, 2021 /PRNewswire/ -- In an effort to increase access to testosterone replacement therapy for men, Colorado-based startup Truman Rx (Truman) is launching an online, innovative telehealth service for testosterone replacement therapy (TRT).
  • Phase I of the launch will focus primarily in Colorado and New Mexico with plans to rapidly expand nationwide in 2021.
  • "\nVisit www.trumanrx.com for more information.\nTruman is a subscription-based telehealth service that helps men access testosterone replacement therapy from the comfort of their homes.
  • The Truman model is designed to be a better experience than brick-and-mortar clinics by providing therapy via videoconference and direct-to-consumer shipping.

CBD Giant Premium Jane Introduces Novel Sleep-Aid Formula With CBN, GABA

Retrieved on: 
Thursday, April 1, 2021
Receptor agonists, Branches of biology, Drugs, Cannabinoids, Natural phenols, Orphan drugs, Aromatase inhibitors, Medicinal plants, Cannabinol, Melatonin, Chamomile, CBN

SCOTTSDALE, Arizona, April 1, 2021 /PRNewswire/ --American CBD giant Premium Jane has introduced a new range of infused products that are specifically engineered to help individuals improve their nightly sleep patterns.

Key Points: 
  • SCOTTSDALE, Arizona, April 1, 2021 /PRNewswire/ --American CBD giant Premium Jane has introduced a new range of infused products that are specifically engineered to help individuals improve their nightly sleep patterns.
  • The products contain a novel formulation of 25mg CBD extract, as well as infused amounts of CBN, GABA, melatonin, and chamomile.
  • The inclusion of CBN (cannabinol) is particularly novel across the greater CBD market, with few brands utilizing the little-known cannabinoid.
  • "It's been an ongoing goal of our development team to formulate a unique, specifically-engineered sleep-aid formula," says Premium Jane CEO Jeff Yauck.

Global N,N-Diethyl-N-methylamine (CAS 616-39-7) Market Report 2021: Applications, Manufacturing Methods, Patents, Trends and Developments, Market Prices - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Chemicals, Plastics, Manufacturing, Psychoactive drugs, Receptor agonists, Drugs, Alkylamines, Methylamine, MDMA

The "N,N-Diethyl-N-methylamine (CAS 616-39-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "N,N-Diethyl-N-methylamine (CAS 616-39-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of N,N-Diethyl-N-methylamine.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with N,N-Diethyl-N-methylamine market trends and forecast, distinguish N,N-Diethyl-N-methylamine manufacturers and suppliers.

Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

Retrieved on: 
Tuesday, March 2, 2021
Triptans, Drugs, Receptor agonists, Serotonin receptors, Sumatriptan, Cipla, Migraine, Nasal spray, GlaxoSmithKline

MUMBAI, India, March 2, 2021 /PRNewswire/ --Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mgfrom the United States Food and Drug Administration (U.S. FDA).

Key Points: 
  • MUMBAI, India, March 2, 2021 /PRNewswire/ --Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mgfrom the United States Food and Drug Administration (U.S. FDA).
  • Cipla's Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version ofGlaxoSmithKline's Imitrex Nasal Spray.
  • Imitrex Nasal Spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
  • According to IQVIA (IMS Health), Imitrex Nasal Spray 20mg and its generic equivalents had US sales of approximately $53.3M for the 12-month period ending December 2020.